Biomx INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

AMEX

30 Apr 2026

PHGE

10-K/A: BiomX Files 10-K/A with Major Board and Management Overhaul

BiomX Inc. filed an amendment to its 2025 Annual Report, detailing a complete turnover of its executive leadership team and significant changes to its Board of Directors.

AMEX

19 Feb 2026

PHGE

Biomx INC

10-K: BiomX Faces Going Concern Doubt Amid Restructuring, Capital Raise

BiomX Inc. reported significant losses and a going concern warning, alongside a strategic pivot, workforce reduction, and a new $3.0 million capital raise contingent on stockholder approval.

AMEX

25 Mar 2025

PHGE

Biomx INC

10-K: BiomX Inc. Reports 2024 Annual Results, Highlights Clinical Progress and Financial Position

BiomX Inc. files its 2024 10-K, detailing clinical advancements in phage therapy for cystic fibrosis and diabetic foot osteomyelitis, alongside its financial status and future outlook.

AMEX

4 Apr 2024

PHGE

Biomx INC

10-K: BiomX Inc. Details Securities Registered Under Exchange Act

BiomX Inc. outlines the terms of its registered securities, including common stock, units, and warrants, all listed on the NYSE American Stock Market.